Author | Clinical target delineation and prescribed dose | Analyzed recurrent patients | Proportion of central recurrence | |
---|---|---|---|---|
(year) | CTV1 (initial field) | CTV2 (boost field) | ||
Brandes et al. [6] | Enhanced tumor area according to preoperative imaging plus 2–3 cm | None (identical with initial field) | 79 | 72.2%a |
60 Gy in 30 fractions | ||||
Milano et al. [7] | Edema plus 2 cm | Residual tumor/resection cavity plus 2–2.5 cm | 39 | 80%b |
46–50 Gy in 23–25 fractions | ||||
60 Gy in 30 fractions | ||||
Minniti et al. [8] | Residual tumor/resection cavity plus 2 cm | Residual tumor/resection cavity plus 1–2 cm | 105 | 75.2%c |
50 Gy in 25 fractions | 60 Gy in 30 fractions | |||
McDonald et al. [9] | Edema plus 0.5–1.2 cm | Residual tumor/resection cavity plus 0–1 cm | 41 | 78%d |
46–54 Gy in 23–30 fractions | ||||
60 Gy in 30 fractions | ||||
Dobelbower et al. [10] | Primary tumor and surrounding edema plus 0.5 cm on postoperative imaging | Residual tumor/resection cavity plus 0.5 cm | 20 | 90%a |
60Gy in 30 fractions | ||||
46 Gy in 23 fractions | ||||
Present Study | Residual tumor/resection cavity plus 2 cm and edema | Residual tumor/resection cavity plus 0 cm | 21 | 66.7% |
50–54 Gy in 25–30 fractions | 60 Gy in 30 fractions |